SureNano Science’s GEP-44 Triple Agonist Targets Next-Generation GLP-1 Market

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has been featured in a BioMedWire editorial that examines the evolution of GLP-1 therapies and the emerging innovation in obesity and metabolic disease treatment. The editorial focuses on SureNano’s subsidiary GlucaPharm Inc. and its GEP-44 program, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in the rapidly expanding GLP-1 market.

The GLP-1 market has seen significant growth driven by demand for therapies targeting obesity, type 2 diabetes and related chronic conditions. Current treatments, while effective, often require injections and can have tolerability issues. SureNano’s GEP-44 aims to address these limitations by offering a triple agonist that targets multiple receptors, potentially leading to better outcomes and the possibility of non-injectable delivery.

According to the press release, SureNano Science is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets. The company has acquired GlucaPharm Inc., which is developing GEP-44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery, as referenced in a press release dated February 23, 2026.

In addition to its pharmaceutical focus, SureNano Science also engages in the sale and distribution of the SureNano surfactant, a ready-to-mix food grade compound for high performance nanoemulsions. This surfactant enhances bioavailability, clarity, and taste in products. The company holds exclusive distribution licenses for the surfactant in Canada, Oklahoma, and Colorado.

The editorial underscores the importance of next-generation therapies as the obesity and metabolic disease market continues to expand. With GEP-44, SureNano aims to differentiate itself by offering a therapy that could be more effective and easier to administer than current options. The company’s shift toward becoming a pharmaceutical-focused entity through the advancement of GEP-44 highlights its strategic pivot to address large and growing global health markets.

For more information about SureNano Science, visit the company’s newsroom at https://ibn.fm/SURNF. The full press release can be accessed at https://ibn.fm/AGdi9.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is SureNano Science’s GEP-44 Triple Agonist Targets Next-Generation GLP-1 Market.

The post SureNano Science’s GEP-44 Triple Agonist Targets Next-Generation GLP-1 Market appeared first on citybuzz.